About Jerini
Jerini is a company based in Berlin (Germany) founded in 1994 was acquired by Shire in July 2008. Jerini has raised $76.16 million across 3 funding rounds from investors including Takeda Pharmaceuticals, 3i Group and Life Sciences Partners. Jerini operates in a competitive market with competitors including Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
- Headquarter Berlin, Germany
- SectorsHealthcare
- Website jerini.com
- Acquired by Shire (Jul 2008)
- Total Equity Funding$76.16M (USD)
in 3 rounds
- Latest Funding Round$20.15M (USD), Series B
Feb 2005
- InvestorsTakeda Pharmaceuticals
& 10 more
- Acquired byShire
(Jul 2008)
Funding Insights of Jerini
Jerini has successfully raised a total of $76.16M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $20.15 million completed in February 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $76.16M
- Total Rounds 3
- Last Round Series B — $20.15M
- First Round $18M
(Nov 2001)
- Investors Count 10
All 3 funding rounds of Jerini with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2005 | $20.15M | Series B | – | NGN Capital, Life Sciences Partners | |
| Jun 2004 | $38.02M | Series B | – | TVM Capital Life Science, 3i Group | |
| Nov 2001 | $18M | Series A | – | PolyTechnos Venture Partners, 3i Group | – |
11 investors in total: 11 institutional.
Investors in Jerini
Jerini has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals, 3i Group and Life Sciences Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
NGN Capital is engaged in venture capital investments. | – | ngncapital.com | New York, United States | |
Private equity firm focused on mid-market businesses | 1945 | 3i.com | London, United Kingdom | |
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
- | – | healthcap.eu | - | |
- | – | 3ibioscience.com | - | |
Venture capital firm focused on multiple sectors | – | ibbventures.de | Berlin, Germany | |
Venture capital is provided to early-stage and growth startups. | 1997 | bmp.com | Berlin, Germany | |
Stage-agnostic investments are directed toward European startups in key sectors. | – | polytechnos.com | Munich, Germany | |
- | – | tvmvc.com | - | |
Life Science focused early stage VC firm investing in Europe, Canada, the USA and Asia | – | tvm-lifescience.com | Munich, Germany |
Investor details for Jerini
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Jerini
4 dated milestones of Jerini across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Jerini is founded.
- Funding First funding round of $18.0M.
- Funding Latest funding round, Series B, of $20.1M.
- Exit Acquired by Shire.
Competitors of Jerini
Jerini operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| geminitherapeutics.com | 2015 | Cambridge, United States | $44.5M | 45 | Developer of precision therapeutics for dry AMD and rare genetic diseases | |
| biomarin.com | 1997 | San Rafael, United States | $37.5M | 2,124 | Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical. | |
| mirumpharma.com | 2018 | Menlo Park, United States | $120M | 196 | Small molecule therapeutics are developed for rare diseases treatment. | |
| homologymedicines.com | 2015 | Lexington, United States | $127M | 221 | Developer of gene therapies for rare genetic diseases | |
| immusoft.com | 2009 | Seattle, United States | $44.13M | – | B cells are programmed as biofactories for therapeutic protein delivery. | |
| pharvaris.com | 2015 | Leiden, Netherlands | $164.21M | – | Orally deliverable bradykinin B2 antagonists are developed for hereditary angioedema. | |
| proqr.com | 2012 | Leiden, Netherlands | $57.99M | – | RNA-based therapeutics are developed for genetic retinal disorders. | |
| aeglea.com | 2013 | Austin, United States | $56M | 81 | Drugs for rare metabolic disorders are developed and advanced. |
Detailed competitors of Jerini
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Jerini
Websites that share an audience with Jerini (jerini.com).
Websites whose visitors overlap most with Jerini. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cambrex.com | 100% | 35K | #883,665 | View details | |
| integragen.com | 100% | – | #10,926,163 | View details | |
crimsonpharma.com | crimsonpharma.com | 100% | – | – | – |
scottish-biomedical.com | scottish-biomedical.com | 100% | – | – | – |
| insmed.com | 100% | 68.8K | #433,178 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Jerini
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Similar companies to Jerini
10 companies that operate in the same segment as Jerini (Rare Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing. | 2013 | Basel, Basel-stadt, Switzerland | USD 127 M | USD 37.31 M | 393 | |
Gene therapies for rare diseases are developed to treat patients. | 2020 | Columbus, Ohio, United States | USD 250 M | – | – | |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | 2015 | Cambridge, Massachusetts, United States | USD 114.67 M | – | 45 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals. | 2019 | Menlo Park, California, United States | USD 90 M | USD 175.11 M | 427 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Jerini
Jerini was founded in 1994 and raised its 1st funding round 7 years after it was founded.
Jerini is headquartered in Berlin, Germany. It is registered at Berlin, Berlin, Germany.
Jerini is a funded company, having raised a total of $76.16M across 3 funding rounds to date. The company's 1st funding round was a Series A of $18M, raised on Nov 2001.
Founded in 1994 in Berlin, Germany, the biotechnology company focused on late-stage development of Bradykinin hormone inhibitors. Firazyr (icatibant) was advanced as an orphan drug for hereditary angioedema, a rare genetic disorder. The firm was listed on the Frankfurt stock exchange in 2005 and acquired by Shire Plc in 2008. FDA approval for Firazyr was granted in 2011, while RD assets were purchased by 3B Pharma in 2009.
Jerini's top competitors include Alnylam, BioMarin Pharmaceutical and Pharvaris.
Jerini has 11 investors. Key investors include Takeda Pharmaceuticals, 3i Group, Life Sciences Partners, NGN Capital, and Healthcap.
Yes. Jerini was acquired by Shire in July 2008.